Sirturo® (bedaquiline) – Expanded indication
July 28, 2025 - The FDA approved Janssen’s Sirturo (bedaquiline), as part of combination therapy in adult and pediatric patients (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid.